Precision medicine is a medical model that proposes the customization of medical
treatments to the individual patient, as opposed to a one-drug-fits-all model. Such a …

Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …

Aims Guidelines recommend the use of potent P2Y12 inhibitors over clopidogrel for the
reduction of ischaemic events in patients with acute coronary syndrome (ACS). However …

The synergistic blockade of the key platelet signaling pathways of cyclooxygenase-1
blockade and P2Y12 signaling by combining aspirin plus a potent P2Y12 inhibitor …

Background Very short (≤ 3 months) duration of dual antiplatelet therapy (VSDAPT) has
recently been proposed after percutaneous coronary intervention (PCI) with drug-eluting …

Stable coronary artery disease (CAD) has recently been replaced by a new entity described
as chronic coronary syndrome (CCS). This new entity has been developed based on a …

Introduction Clopidogrel is the most frequently utilized P2Y12 inhibitor and is characterized
by broad interindividual response variability resulting in impaired platelet inhibition and …

Coronary artery revascularisation can be performed surgically or percutaneously. Surgery is
associated with higher procedural risk and longer recovery than percutaneous interventions …

Introduction Dual antiplatelet therapy (DAPT) following percutaneous coronary intervention
(PCI) reduces major adverse cardiovascular events (MACE) and stent thrombosis. However …

Based on a wealth of evidence, aspirin is one of the cornerstones of secondary prevention of
cardiovascular disease. However, despite several studies showing efficacy also in primary …